Ginkgo biloba does - And does not-prevent acute mountain sickness

Wilderness and Environmental Medicine

Volumn 20, Issue 1, 2009, Pages 66-71

  Leadbetter, Guy ^a,c   Keyes, Linda E ^b   Maakestad, Kirsten M ^d   Olson, Sheryl ^e   Van Tissot Patot, Martha C ^b,c   Hackett, Peter H ^b,e  

^a and Mass Communication   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d University of Missouri   (United States)

^e Institute for Altitude Medicine   (United States)

Author keywords

Acute mountain sickness; Altitude; Ginkgo; Hypoxia

Indexed keywords

BILOBALIDE; GINKGO BILOBA EXTRACT; GINKGOLIDE A; GINKGOLIDE B; GINKGOLIDE C; ISORHAMNETIN; KAEMPFEROL; PLACEBO; QUERCETIN;

ADULT; ALTITUDE DISEASE; ARTICLE; CHEMICAL COMPOSITION; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; MALE; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL;

EID: 62449275228     PISSN: 10806032     EISSN: None     Source Type: Journal    
DOI: 10.1580/08-WEME-BR-247.1     Document Type: Article

References (14)

1. Chow T, Browne V, Heileson HL, Wallace D, Anholm J, Green SM. Ginkgo biloba and acetazolamide prophylaxis for acute mountain sickness: a randomized, placebo-controlled trial. Arch Intern Med. 2005;165:296-301.
2. Basnyat B, Gertsch JH, Hoick PS, et al. Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial. High Alt Med Biol. 2006;7:17-27.
3. Gertsch JH, Seto TB, Mor J, Onopa J. Ginkgo biloba for the prevention of severe acute mountain sickness (AMS) starting one day before rapid ascent. High Alt Med Biol. 2002;3:29-37.
4. Roncin JP, Schwartz F, D'Arbigny P. EGb 761 in control of acute mountain sickness and vascular reactivity to cold exposure. Aviat Space Environ Med. 1996;67:445-452.
5. Gertsch JH, Basnyat B, Johnson EW, Onopa J, Hoick PS. Randomised, double blind, placebo-controlled comparison of Ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT). BMJ. 2004;328:797-801.
6. Moraga FA, Flores A, Serra J, Esnaola C, Barriento C. Ginkgo biloba decreases acute mountain sickness in people ascending to high altitude at OUague (3696 m) in northern Chile. Wilderness Environ Med. 2007;18:251- 257.
7. Ernst E. The risk-benefit profile of commonly used herbal therapies: ginkgo, St. John's wort, ginseng, Echinacea, saw almetto, and kava. Ann Intern Med. 2002;136:42-53.
8. Sampson JB, Cymerman A, Burse RL, Maher JT, Rock PB. Procedures for the measurement of acute mountain sickness. Aviat Space Environ Med. 1983;54:1063-1073.
9. Roach RC, Bartsch P, Oelz O, Hackett PH. The Lake Louise acute mountain sickness scoring system. In: Sutton JR, Houston CS, Coates G, eds. Hypoxia and Molecular Medicine. Burlington, VT: Queen City Press; 1993:272-274.
10. Hackett PH, Roach RC. High-altitude illness. N Engl J Med. 2001;345:107-114.
11. Dumont L, Mardirosoff C, Tramer MR. Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review. BMJ. 2000;321:267-272.
12. Lobstein A, Rietsch-Jako L, Haag-Berrurier M, Anton R. Seasonal variations of the flavonoid content from Ginkgo biloba leaves. Planta Med. 1991;57:430-433.
13. Kressmann S, Muller WE, Blume HH. Pharmaceutical quality of different Ginkgo biloba brands. J Pharm Pharmacol. 2002;54:661-669.
14. Ding S, Dudley E, Plummer S, Tang J, Newton RP, Brenton AG. Quantitative determination of major active components in Ginkgo biloba dietary supplements by liquid chromatography/mass spectrometry. Rapid Commun Mass Spectrom. 2006;20:2753-2760.